Prophylactic Effect of Butea monosperma against Cisplatin-Induced Nephrotoxicity in Rats
Cisplatin is an effective chemotherapeutic agent for solid tumors; however its use is limited by nephrotoxicity. The current study investigated the effect of Butea monosperma in cisplatin-induced nephrotoxicity and oxidative stress in rats. Kidneys have a vital role in the normal physiology of humans. Worldwide chronic kidney disease has become a major cause for disability and in worst circumstances leads to death. Major renal disorders occur due to diabetes and its complications termed as diabetic nephropathy (DN). The animals were divided into four groups of six rats each (n=6). The control group (Group 1) received 1%CMC, Group 2 received only cisplatin, a 7 days of extract of Butea monosperma (200 mg/kg bwt) pre-treatment was applied to the animals in Group 3 before administration of cisplatin; a 7 days of extract of Butea monosperma was performed following administration of cisplatin for the animals in Group 4. Cisplatin (6 mg/kg) was intraperitoneally injected as a single dose and extract of Butea monosperma (200 and 400 mg/kg bwt) was administered by gavage in 1%CMC. Biochemical and histopathological methods were utilized for evaluation of the nephrotoxicity. The concentrations of creatinine, uric acid and blood urine nitrogen, in plasma and levels of malondialdehyde and reduced glutathione as well as glutathione peroxidase and catalase activities were determined in kidney tissue. Administration of cisplatin to rats induced a marked renal failure, characterized with a significant increase in plasma creatinine and uric acid and Blood urea nitrogen. levels of rats received cisplatin alone were significantly different compared to control group but they had higher kidney malondialdehyde, and lower reduce glutathione concentrations, superoxide dismutase and catalase activities. Extract of B. monosperma administration produced amelioration in biochemical indices of nephrotoxicity in both serum and kidney tissues when compared to toxic inducer group; pre-treatment with extract of Butea monosperma being more effective. Results from this study indicated that the novel natural antioxidant extract of B. monosperma might have protective effect against cisplatin-induced nephrotoxicity and oxidative stress in rat.
2. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. Diabetes Atlas. 3rd ed. Brussels: International Diabetes Federation, 2006; 15-109.
3. Kamboj VP. Herbal medicine. Curr Sci, 2000; 78(1):35-39.
4. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol, 2002; 42(3):317-325.
5. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int, 2008; 73(9):994-1007.
6. Santoso J, Lucci J, Coleman R, Schafer I., Hannigan E. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: arandomized trial. Cancer Chemother Pharmacol, 2003; 52(1):13-18.
7. Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J pharmacol Exp Ther, 2008; 327(2): 300-307.
8. Mora L, Antunes LM, Francescato HD, Bianchi M. The effects of oral glutamine on cisplatininduced nephrotoxicity in rats. Pharmacol Res, 2003; 47(6):517-22.
9. Ognjanovic BI, Djordjevic NZ, Matic MM, Obradovic JM, Mladenovic JM, Stajn AS. Lipid peroxidative damage on cisplatin exposure and alterations in antioxidant defense system in rat kidneys: a possible protective effect of selenium. Int J Mol Sci, 2012; 13(2):1790-1803.
10. Florea AM, Büsselberg D. Cisplatin as an antitumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers, 2011; 3(1):1351-1371.
11. Humanes B, Lazaro A, Camano S, Moreno- Gordaliza E, Lazaro JA, Blanco-Codesido M. Cilastatin protects against cisplatin-inducednephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int, 2012; 82(6):652-663.
12. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates cisplatin induced renal injury: importance of superoxide. Clin J Am Soc Nephrol, 2001;12(12):2683-2690.
13. Baldew GS, Van den Hamer, CJ, Los G, Vermeulen NP, de Goeij JJ, McVie JG. Selenium-induced protection against cis-diamminedichloroplatinum (II) nephrotoxicity in mice and rats. Cancer Res, 1989; 49(11): 3020-3023.
14. Francescato HDC, Costa RS, Camargo SMR, Zanetti MA, Lavrador MA, Bianchi MLP. Effect of dietary oral selenium on cisplatin induced nephrotoxicity in rats. Pharmacol Res, 2001; 43:77-82.
15. Appenroth D, Fröb S, Kersten L, Splinter F-K, Winnefeld K. Protective effects of Vitamins E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol. 1997; 71:677-83.
16. Antunes LMG, Darin JDC, Bianchi MLP. Protective effects of Vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats, a dose-dependent study. Pharmacol Res, 2000; 41:405-11.
17. Antunes LMG, Araújo MCP, Darin JDC, Bianchi MLP. Effects of the antioxidants curcumin and Vitamin C on cisplatin-induced clastogenesis in Wistar rat bone marrow cells. Mutat Res, 2000; 465:131-7.
18. Silva CR, Antunes LMG, Bianchi MLP. Antioxidant action of bixin against cisplatin-induced chromosome aberrations and lipid peroxidation in rats. Pharmacol Res. 2001; 43(6):561-6.
19. Kroning R, Lichestenstein AK, Nagami GT. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubular epithelial cell lines. Cancer Chemother Pharmacol, 2000; 45:43-9.
20. The Wealth of India-Raw Materials. CSIR, New Delhi, 1988; 2b:341-346.
21. Chopra RN, Chopra JC, Handa KL, Kapur LD. Indigenous drugs of India, 1958.
22. Chopra RN, Chopra IC. Indigenous drugs of India. Academic publishers, 1933.
23. Nadkarni KM. Indian Materia Medica. 2002; 1:223-225.
24. Sequeira V, Bezkorowajnyj PG. Improved management of Butea monosperma (Lam.) Taub for lac production in India. For Ecol Manag, 1998; 102(2-3):225-234.
25. Kokate CK. Practical Pharmacognosy. Vallabh Prakashan, New Delhi, 1994; 4:110-111.
26. Greggi Antunes LM, Darin JDC, Bianchi M. Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res, 2001; 43 (2):145-150.
27. Yilmaz HR, Iraz M, Sogut S, Ozyurt H, Yildirim Z, Akyol O, Gergerlioglu S. The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats. Pharmacol Res, 2004; 50 (3):287-290
28. OECD, 1994. OECD 423, Guidelines for acute oral toxicity. Guidelines for the Testing of Chemicals. Organization for Economic.
29. Matsushima H, Yonemura K, Ohishi K, Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med, 1998; 131(6):518-526.
30. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem, 1979; 95:351-358.
31. Ellman G. Tissue sulphydryl groups. Arch Biochem Biophys, 1959; 82:70-77.
32. Aebi H. Catalase. In: Bergmeyer, H.U. (Ed.), Methods in Enzymatic Analysis. Academic Press, New York, 1983; pp. 276-286.
33. Matsushima H, Yonemura K, Ohishi K, Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med, 1998; 131(6):518-526.
34. Sugihara K, Nakano S, Koda M, Tanaka K, Fukuishi N, Gemba M. Stimulatory effect of cisplatin on lipid peroxidation in renal tissues. Jpn J Pharmacol, 1987; 43:247-52.
35. Kruidering, M, Van De Water B, De Heer E, Mulder GJ, Nagelkerke JF. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol ExpTher, 1997; 280(2):638-649.
36. Chirino YI, Sanchez-Gonzalez DJ, Martinez CM, Cruz C, Pedraza-Chaverri J. Protective effects of apocynin against cisplatin-induced oxidative stress and nephrotoxicity. Toxicology, 2008; 245:18-23.
37. Lalila A, Ola H, Hossam A, Mohamed M, Sayed A. Effect of cremophor-EL on cisplatininduced organ toxicity in normal rat. J Egypt Natl Canc Inst, 2001; 13(2):139-45.
38. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep, 2003; 10(6):1663-82.
39. Galea AM, Murray V. The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim Biophys Acta, 2002; 1579(2-3):142-52.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).